FENNEC PHARMACEUTICALS INC. (FENC) Operating Margin
- Operating margin · 12 months: Value -1.90%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1.90% | Operating income / revenue. Period ending 2026-06-30. $-1.12M ÷ $59.22M × 100 ≈ -1.90% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -1.12M USD | Operating Income (Loss) |
| Revenue | 59.22M USD | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 216.00K USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-1.12M | $59.22M | (m) | $216.00K | (m) | -1.90% |
| 2026-03-31 | $-5.59M | $51.00M | (m) | $205.00K | (m) | -10.97% |
| 2025-12-31 | $-6.28M | $44.64M | (m) | $250.00K | (m) | -14.07% |
| 2025-09-30 | $-4.66M | $38.79M | (m) | $280.00K | (m) | -12.02% |
| 2025-06-30 | $-9.68M | $33.30M | (m) | $348.00K | (m) | -29.06% |
| 2025-03-31 | $-11.98M | $30.91M | (m) | $398.00K | (m) | -38.76% |
| 2024-12-31 | $2.57M | $47.54M | (m) | $307.00K | (m) | 5.40% |
| 2024-09-30 | $1.68M | $49.35M | (m) | $289.00K | (m) | 3.41% |
| 2024-06-30 | $5.87M | $48.89M | (m) | $204.00K | (m) | 12.00% |
| 2024-03-31 | $6.24M | $44.95M | (m) | $55.00K | (m) | 13.89% |
| 2023-12-31 | $-12.77M | $21.25M | $1.26M | $56.00K | (m) | -60.09% |
| 2023-09-30 | $-17.09M | (m) | (m) | $141.00K | (m) | (m) |
| 2023-06-30 | $-23.97M | (m) | (m) | $975.00K | (m) | (m) |
| 2023-03-31 | $-24.31M | (m) | (m) | $2.10M | (m) | (m) |
| 2022-12-31 | $-22.59M | (m) | $86.00K | $3.53M | (m) | (m) |
| 2022-09-30 | $-20.66M | (m) | (m) | $3.94M | (m) | (m) |
| 2022-06-30 | $-16.93M | (m) | (m) | $4.33M | (m) | (m) |
| 2022-03-31 | $-15.85M | (m) | (m) | $4.00M | (m) | (m) |
| 2021-12-31 | $-17.22M | (m) | (m) | $4.98M | (m) | (m) |
| 2021-09-30 | $-16.36M | (m) | (m) | $5.68M | (m) | (m) |
| 2021-06-30 | $-18.05M | (m) | (m) | $5.81M | (m) | (m) |
| 2021-03-31 | $-18.97M | $200.00K | (m) | $6.13M | (m) | -9486.50% |
| 2020-12-31 | $-17.89M | (m) | (m) | $5.11M | (m) | (m) |
| 2020-09-30 | $-18.19M | $0.00 | (m) | $5.05M | (m) | (m) |
| 2020-06-30 | $-14.20M | $0.00 | (m) | $4.48M | (m) | (m) |
| 2020-03-31 | $-14.16M | $0.00 | (m) | $5.33M | (m) | (m) |
| 2019-12-31 | $-13.01M | $0.00 | (m) | $5.61M | (m) | (m) |
| 2019-09-30 | $-12.46M | $0.00 | (m) | $6.16M | (m) | (m) |
| 2019-06-30 | $-13.45M | $0.00 | (m) | $7.16M | (m) | (m) |
| 2019-03-31 | $-11.30M | $0.00 | (m) | $5.99M | (m) | (m) |
| 2018-12-31 | $-10.41M | $0.00 | (m) | $5.01M | (m) | (m) |
| 2018-09-30 | $-9.82M | $0.00 | (m) | $4.17M | (m) | (m) |
| 2018-06-30 | $-9.16M | $0.00 | (m) | $2.87M | (m) | (m) |
| 2018-03-31 | $-7.97M | $0.00 | (m) | $2.40M | (m) | (m) |
| 2017-12-31 | $-6.95M | $0.00 | (m) | $1.94M | (m) | (m) |
| 2017-09-30 | $-5.58M | $0.00 | (m) | $1.22M | (m) | (m) |
| 2017-06-30 | $-3.96M | $0.00 | (m) | $844.00K | (m) | (m) |
| 2017-03-31 | $-3.19M | $0.00 | (m) | $650.00K | (m) | (m) |
| 2016-12-31 | $-2.87M | $0.00 | (m) | $472.00K | (m) | (m) |
| 2016-09-30 | $-2.28M | $0.00 | (m) | $369.00K | (m) | (m) |
| 2016-06-30 | $-2.05M | $0.00 | (m) | $345.00K | (m) | (m) |
| 2016-03-31 | $-1.89M | $0.00 | (m) | $260.00K | (m) | (m) |
| 2015-12-31 | $-1.89M | $0.00 | (m) | $256.00K | (m) | (m) |
| 2015-09-30 | $-2.13M | $0.00 | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-2.41M | $0.00 | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-2.79M | $0.00 | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-2.88M | $0.00 | (m) | (m) | (m) | (m) |
| 2014-09-30 | $-2.50M | $0.00 | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-1.93M | $0.00 | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-1.93M | $0.00 | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-1.93M | $0.00 | (m) | $579.00K | (m) | (m) |
| 2013-09-30 | $-2.64M | $0.00 | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-3.22M | $0.00 | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-3.54M | $0.00 | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-3.62M | $0.00 | (m) | $2.08M | (m) | (m) |
| 2012-09-30 | $-3.40M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-3.71M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-3.03M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-3.44M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-4.60M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |